Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer by Cecilia Olsson Ladjevardi, Marcus Skribek, Anthoula Koliadi, Viktoria Rydén, Ali Inan El-Naggar, Evangelos Digkas, Antonios Valachis, Gustav J. Ullenhag

Subjects: Get full text

Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy by Myrna Luna-Gutiérrez, Erika Azorín-Vega, Rigoberto Oros-Pantoja, Blanca Ocampo-García, Pedro Cruz-Nova, Nallely Jiménez-Mancilla, Gerardo Bravo-Villegas, Clara Santos-Cuevas, Laura Meléndez-Alafort, Guillermina Ferro-Flores

Subjects: Get full text

Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1 by Coco Duizer, Moniek Salomons, Merel van Gogh, Sanne Gräve, Freke A. Schaafsma, Maaike J. Stok, Merel Sijbranda, Raghuvandhanan Kumarasamy Sivasamy, Rob J. L. Willems, Marcel R. de Zoete

Subjects: Get full text

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer by Huiping Qiang, Yue Wang, Yao Zhang, Jingwen Li, Lincheng Zhang, Huawei Du, Xuxinyi Ling, Shuhui Cao, Yan Zhou, Runbo Zhong, Hua Zhong

Subjects: Get full text

负性共刺激分子PD-L1在非肌层浸润性膀胱癌的表达 及其对术后膀胱灌注治疗的影响

Subjects: Get full text

A remarkable and durable response to tislelizumab treatment of an anaplastic thyroid carcinoma without targetable genomic alterations: a case report by Jingjing Chai, Jiaqi Lv, Jian Xiong, Xiuwen Chen, Senyuan Luo, Zhiguo Luo, Zhiguo Luo, Ming Luo

Subjects: Get full text

Dual-release hydrocortisone treatment improves serum and peripheral blood mononuclear cell inflammatory and immune profiles in patients with autoimmune primary adrenal insufficienc... by Laura Tomasello, Antonina Coppola, Giuseppe Pizzolanti, Giuseppe Pizzolanti, Carla Giordano, Giorgio Arnaldi, Valentina Guarnotta

Subjects: Get full text

EXPRESSION AND CLINICAL CORRELATION OF PD-1/PD-L1 AND VE1(BRAFP.V600E) IN PEDIATRIC LANGERHANS CELL HISTIOCYTOSIS by sneha tandon, Sheila Weitzman, Brooklyn Joyce, Bryan Maguire, Derek Stephens, James Whitlock, Cynthia Hawkins, Bo-Yee Ngan, Oussama Abla

Subjects: Get full text

The impact of PD-L1 expression status on the prognosis of ALK-positive lung cancer patients by Li Wang, Yingjun Kong, Yao Zhang, Chuanyong Mu

Subjects: Get full text

Biomarkers in metastatic castration-resistant prostate cancer for efficiency of immune checkpoint inhibitors by Zixi Wu, Junbiao Zhang, Le Li, Zhihua Wang, Chunguang Yang

Subjects: Get full text

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison by Wei Chen, Wei Chen, Soichiro Yoshida, Noriyoshi Miura, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Hajime Tanaka, Yasuhisa Fujii

Subjects: Get full text

PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) by Stefania Angelicola, Francesca Giunchi, Francesca Ruzzi, Mariateresa Frascino, Mary Pitzalis, Laura Scalambra, Maria Sofia Semprini, Olga Maria Pittino, Chiara Cappello, Irene Siracusa, Ilaria Candida Chillico, Martina Di Noia, Cristian Turato, Silvia De Siervi, Francesco Lescai, Teresa Ciavattini, Giulia Lopatriello, Luca Bertoli, Hugo De Jonge, Luisa Iamele, Annalisa Altimari, Elisa Gruppioni, Andrea Ardizzoni, Marzia Rossato, Francesco Gelsomino, Pier-Luigi Lollini, Arianna Palladini

Subjects: Get full text

Sinonasal small-cell carcinoma combined concurrently with small-cell lung carcinoma: case report and literature review by Rencui Quan, Rencui Quan, Ling Han, Shihai Wu, Xianming Li

Subjects: Get full text

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung canc... by Ke Wang, Ke Wang, Chuangjie Zheng, Chuangjie Zheng, Xinrong Chen, Xinrong Chen, Penghui Lin, Mengge Lin, Cuizhen Chen, Linzhu Zhai

Subjects: Get full text

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients by Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Jiwen Zhang, Xingyu Wei, Xingyu Wei, Fei Li, Fei Li, Dehua Liao

Subjects: “…PD-1/PD-L1 inhibitors…”
Get full text

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinoma by Dantong Sun, Helei Hou, Feiyue Feng, Weizheng Wu, Jingyu Tan, Tongji Xie, Jiayu Liu, Jinsong Wang, Haili Qian, Junling Li, Puyuan Xing

Subjects: Get full text

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors by Meijuan Zhai, Shiliang Ji, Haoran Hu, Yongjie Wu, Yi Shi, Ruifang Zhu, Yiguo Jiang, Yang Yang

Subjects: Get full text

Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients by Tara Seery, Lennie Sender, Omid Jafari, Frank Jones, Patricia Spilman, Sandeep B. Reddy, Patrick Soon-Shiong

Subjects: Get full text

Repression of the stress granule protein G3BP2 inhibits immune checkpoint molecule PD‐L1 by Yanhong Zhang, Changli Yue, Anna M. Krichevsky, Igor Garkavtsev

Subjects: Get full text

Cyclooxygenase-2/prostaglandin E2 inhibition remodulated photodynamic therapy-associated immunosuppression for enhanced cancer immunotherapy by Tao Xu, Kehan Liu, Shuqi Mi, Yao Yao, Mengyao Zhang, Shujuan Xue, Feng Zhi, Sally-Ann Cryan, Dawei Ding

Subjects: Get full text